← All Compounds
Mechanism Synthetic analog of growth hormone-releasing hormone (GHRH). Stimulates pulsatile GH release from the pituitary. The "no DAC" variant has a shorter duration and preserves natural GH pulsatility. Half-Life Approximately 30 minutes Route subcutaneous Frequency 2-3x daily
FDA Category Research peptide (FDA Category 2) Reclassification pending Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
CJC-1295 (no DAC) / Modified GRF 1-29
Cat 2 → Pending Cat 1GH Secretagogue · Research peptide (multiple suppliers)
Synthetic GHRH analog that stimulates pulsatile GH release. The no-DAC variant preserves natural GH pulsatility with a shorter duration of action.
About
Clinical Dosing
100-300 mcg2-3x daily
Not FDA-approved. Currently Category 2 (restricted). Pending return to Category 1. Often paired with Ipamorelin for synergistic GH release.
Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Protocol
Source: Ionescu & Bhayani, Growth Hormone & IGF Research, 2006
| Dose | Duration | Draw (2 mg vial in 2mL) | Notes |
|---|---|---|---|
| 100 mcg | Maintenance | 0.10 mL (10 units) | Standard dose 2-3x/day, often combined with Ipamorelin |
Available Vial Sizes
2 mg
2 mg vial
5 mg
5 mg vial
Citations
- [1]CJC-1295, A Long-Acting GHRH Analog. Growth Hormone & IGF Research, 16(S1), S62. Link(Reviewed: 2026-02-27)